Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to Ionis and AstraZeneca's...

Related Keywords

Australia ,Australian ,Sarah Walters ,Eugene Schneider ,Linkedin ,Ionis Pharmaceuticals ,Drug Administration ,Ionis Pharmaceuticals Inc ,Astrazeneca ,Nasdaq ,Columbia University Irving Medical Center ,Fast Track ,Orphan Drug Designation ,Transthyretin Mediated Amyloid Cardiomyopathy ,Conjugated Antisense ,Serum Vitamin ,Recommended Supplementation ,Prescribing Information ,University Irving Medical Center ,Drug Reduces Death ,Underdiagnosed Form ,Heart Failure ,Markets ,